Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01319916 · ClinicalTrials.gov registry record · Phase 1
Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue
A Phase 1 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01319916 is a Phase 1 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT01319916, a Phase 1 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Open Label Study to Evaluate the Serum Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 into Abdominal Fat Tissue
Interventions
- DRUG ATX-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01319916
The ClinicalTrials.gov registry entry for NCT01319916 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATX-101 is the first listed.
NCT01319916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01319916 about?
NCT01319916 is a clinical study titled "Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue". Open Label Study to Evaluate the Serum Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 into Abdominal Fat Tissue
What is the current status of trial NCT01319916?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01319916?
The interventions under investigation include: ATX-101 (DRUG).
Who is sponsoring clinical trial NCT01319916?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.